IHC Marker - IDH1 Test
About IHC Marker - IDH1 Test
| Field | Value |
|---|---|
| Also Known As | IDH1 R132H IHC Test, IDH1 Mutation Immunostain Test, Isocitrate Dehydrogenase 1 IHC Test, IDH1-R132H Immunohistochemistry Test |
| Sample Type | FFPE Tissue Block |
| Fasting Required | No |
| Report Time | 3 Days |
| Recommended For | Males and females of all ages with suspected brain tumours (gliomas) |
| Price | Starting at ₹3,600 |
What Is an IHC Marker - IDH1 Test?
The IHC marker - IDH1 test is a specialised laboratory test that uses immunohistochemistry to detect a specific protein produced by the IDH1 R132H gene mutation in tumour tissue. A pathologist examines a tissue sample under a microscope after treating it with targeted antibodies. The test is commonly ordered for patients with suspected or confirmed brain tumours, particularly gliomas. It is also known as the IDH1 R132H Immunohistochemistry test and the IDH1 Mutation Immunostain test.
What Does an IHC Marker - IDH1 Test Measure?
The IHC marker - IDH1 test procedure analyses tumour tissue for the presence of a specific mutant protein. The antibody used binds only to the IDH1-mutated (R132H) protein and does not react with the normal version of IDH1. The test evaluates the following:
| Component | What It Shows |
|---|---|
| IDH1 R132H mutant protein | Whether the most common IDH1 mutation is present in the tumour tissue |
| Staining pattern | Strong, diffuse cytoplasmic staining indicates a positive result |
| Tumour vs. normal tissue | Helps distinguish between infiltrating tumour cells and non-cancerous brain tissue changes |
Why Is an IHC Marker - IDH1 Test Done?
Doctors order this test to help classify brain tumours and guide further management. Here is a breakdown of the most common reasons.
Common Symptoms That May Require This Test
A doctor may recommend the IHC marker - IDH1 test after a biopsy when a patient presents with symptoms such as:
- New or worsening headaches
- Seizures with no prior history
- Memory problems or confusion
- Weakness on one side of the body
- Changes in personality or behaviour
- Vision problems
Conditions This Test Can Help Detect
The test helps identify or classify several conditions. These include:
- WHO Grade 2, 3, and 4 diffuse gliomas, including astrocytomas and oligodendrogliomas
- Secondary glioblastoma (a high-grade brain tumour arising from a lower-grade glioma)
- Distinguishing infiltrating gliomas from reactive gliosis (non-cancerous tissue changes)
- Acute myeloid leukemia, chondrosarcoma (a bone tumour), and cholangiocarcinoma (bile duct cancer), where IDH1 mutations have also been identified
How to Prepare and What to Expect
Since this test is performed on tissue rather than blood, the preparation steps are different from routine blood tests.
Do You Need to Fast?
No fasting is required for the IHC marker - IDH1 test. The test is carried out on a tissue block obtained through a biopsy or surgical procedure, not on a blood or urine sample.
Practical Tips Before Your Test
Bringing the right documents helps ensure accurate results. Keep the following in mind:
- Bring a detailed clinical history, including your symptoms, previous test results, and family history
- Carry your doctor's referral letter, which should mention the biopsy site
- Bring any existing histopathology reports if submitting a paraffin block
- Include relevant imaging reports such as MRI, CT scan, or PET scan
- Inform your doctor about all medications you are currently taking
Step-by-Step Procedure
The IHC marker - IDH1 test procedure involves laboratory processing of tissue rather than a direct patient sample collection. Here is how it works:
- A tissue sample is obtained by your doctor through a needle biopsy, incisional biopsy, or surgical removal. No separate collection is required specifically for the IHC test itself.
- The tissue is placed in a formalin solution to preserve it, then embedded in a paraffin wax block. This is known as FFPE (formalin-fixed paraffin-embedded) processing.
- The FFPE block is transported to the laboratory at ambient temperature (18 to 28 degrees Celsius) for processing and analysis.
- Very thin slices are cut from the tissue block using a precision instrument called a microtome and mounted on glass slides.
- The slides undergo deparaffinisation and heat-induced antigen retrieval to remove the wax and unmask target proteins.
- The slides are treated with primary antibodies that specifically target the IDH1 R132H mutant protein, followed by a secondary enzyme and chromogen detection system to make the staining visible as a brown precipitate under a microscope.
- A trained pathologist examines the stained slides to assess whether the IDH1 R132H protein is present and to record the pattern of staining.
Factors That Can Affect Accuracy
Several factors may influence the quality or reliability of staining. These include:
- Age of the paraffin section (fresh sections cut within 6 weeks generally give better results)
- Over-fixation or under-fixation of the tissue during processing
- Environmental conditions affecting the glass slide charge
- Overall specimen handling quality from collection to transport
- Expertise of the pathologist interpreting the stained slides
Understanding Your IHC Marker - IDH1 Test Results
Results from this test are reported as positive or negative based on the presence or absence of IDH1 R132H staining. A pathologist evaluates the pattern and intensity of staining in the context of the tissue morphology.
| Result | Interpretation |
|---|---|
| Positive (mutation detected) | IDH1 R132H mutation is present; supports the diagnosis of an IDH-mutant glioma |
| Negative (no mutation detected) | R132H mutation not identified; other IDH1 or IDH2 mutations may still exist and may require further molecular testing |
Disclaimer: The information in this table is a general guide. Your doctor will interpret your results based on your age, health history, and other factors. Always consult a qualified healthcare professional for personalised medical advice.
Results During Special Conditions
The IDH1 R132H Immunohistochemistry test has a sensitivity of approximately 80% and a specificity of 100% for detecting the R132H variant. In some cases, non-specific background staining or variation in protein expression across different areas of the tumour may affect interpretation. Additionally, older paraffin sections may show reduced antibody reactivity, which can affect result reliability.
Post-Test Guidance and Next Steps
This is a diagnostic tumour marker test, not a routine wellness screen. General guidance includes the following:
- If an IDH-mutant glioma is diagnosed, follow your oncologist's treatment and monitoring plan closely
- Attend all scheduled follow-up appointments for imaging and clinical assessment
- Keep records of all previous histopathology and imaging reports for reference at each consultation
Lupin Diagnostics IHC Marker - IDH1 Test Price
The IHC marker - IDH1 test price at Lupin Diagnostics starts at ₹3,600. This test requires a visit to a Lupin Diagnostics centre for submission of the FFPE tissue block. The table below shows indicative prices:
| City | Approximate Price (₹) |
|---|---|
| BHOPAL | 3600 |
| CHENNAI | 3600 |
| HYDERABAD | 3600 |
| KOLKATA | 3600 |
| NAVI MUMBAI | 3600 |
| PUNE | 3600 |
Disclaimer: Prices are indicative and may vary by location. Please confirm the current price at the time of booking.
How to Book
Booking the IHC marker - IDH1 test online is straightforward. Here are the steps:
- Select the test on the Lupin Diagnostics website
- Choose your city and preferred centre location
- Visit the selected Lupin Diagnostics centre to submit the FFPE tissue block for analysis
- Receive your report via email or WhatsApp within 3 days
Frequently Asked Questions
The IHC marker - IDH1 test is used to detect the IDH1 R132H mutation in tumour tissue. It helps differentiate infiltrating brain tumours (gliomas) from non-cancerous brain tissue changes (reactive gliosis) and acts as a prognostic marker for glioma classification under the WHO 2021 system.
The sample is obtained through a biopsy or surgical removal of tumour tissue performed by your doctor in a hospital or surgical centre. The tissue is then preserved in formalin and embedded in a paraffin block (FFPE), which is submitted to the laboratory for IDH1 R132H Immunohistochemistry testing.
No. This test requires a tissue sample obtained through surgical biopsy or tumour resection, which must be performed in a clinical setting. The FFPE tissue block is then submitted to a specialised laboratory for analysis. Home collection is not available for this test.
A positive result means the IDH1 R132H mutant protein was detected in the tumour tissue. This supports the diagnosis of an IDH-mutant glioma. Patients with this mutation are generally diagnosed at a younger age and tend to have better survival outcomes compared to those with IDH-wildtype tumours.
A negative result means the R132H mutation was not found. However, other less common IDH1 or IDH2 mutations may still be present. In such cases, your doctor may recommend molecular sequencing to check for rarer variants before drawing a final conclusion.
At Lupin Diagnostics, the report is delivered within 3 days. The test is scheduled Monday through Saturday. Processing time may vary based on the condition of the submitted tissue block.
Yes. Clinical history is required when submitting the tissue block for this test. Bring your doctor's referral letter along with relevant imaging reports (MRI, CT scan) and any prior histopathology reports. This information helps the pathologist interpret the staining findings accurately.
IHC Marker - IDH1
